| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 19,630 | 14,920 | 40,000 | 26,540 | 11,240 |
| Sales Growth | +31.57% | -62.70% | +50.72% | +136.12% | unch |
| Net Income | -60,480 | -86,880 | -19,880 | -340 | -22,400 |
| Net Income Growth | +30.39% | -337.02% | -5,747.06% | +98.48% | +79.16% |
Carisma Therapeutics Inc (CARM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Carisma Therapeutics Inc. is a late-stage clinical company which focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's advanced product candidate includes Vicineum(TM). Carisma Therapeutics Inc., formerly known as Sesen Bio Inc., is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31